- Home
- RDCM vs CNTB Comparison
RDCM vs CNTB Comparison
Compare RDCM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | CNTB |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 140.4M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDCM | CNTB |
|---|---|---|
| Price | $10.13 | $0.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $14.00 | $5.88 |
| AVG Volume (30 Days) | 48.8K | ★ 1.6M |
| Earning Date | 11-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,291.47 |
| Revenue Next Year | $6.56 | $74.30 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $0.85 |
| 52 Week High | $16.74 | $3.82 |
Technical Indicators
Market Signals| Indicator | RDCM | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 38.38 |
| Support Level | $10.07 | $0.85 |
| Resistance Level | $10.79 | $2.74 |
| Average True Range (ATR) | 0.23 | 0.08 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 32.20 | 3.46 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.